More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE

uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE

uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline. Read the full article here.…READ MORE

uMETHOD is excited to announce the release of its breakthrough methodology -- called ExtND METHOD -- designed to finally provide a prevention solution to the over 70 million women and men in the USA at risk of Alzheimer’s disease and cognitive decline. The complexity of treating and preventing cognitive decline due to dozens of biological mechanisms and hundreds of interventions is now made straightforward through the application of uMETHOD’s proprietary…READ MORE

Most physicians can assess whether a patient is developing Alzheimer’s disease in five minutes, according to the Alzheimer’s Association. But few general practitioners include the screening in checkups, even though it’s covered as a yearly Medicare benefit. “Honestly, most doctors don’t want to find it,” says Tom Leggett, director of business development for Sonora Quest Laboratories in Tempe. “The uncomfortable truth is when you’re a physician and you find moderate…READ MORE

JANUARY 6, 2020 (KTAR News Photo/Griselda Zetino) PHOENIX — Arizona is projected to have one of the fastest growing rates of Alzheimer’s disease in the country over the next few years, and a clinical lab testing company in the Valley is trying to reverse that. Phoenix-based Sonora Quest Laboratories is working with a tech company called uMETHOD Health to collect patient data through a platform called RestoreU METHOD. The data…READ MORE

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE

Earlier this year the Center for Disease Control and Prevention (CDC) predicted that the burden of Alzheimer’s disease and related dementia (ADRD) in the United States is expected to double by 2060. It is predicted that Arizona has the second highest growth-rate of of Alzheimer’s disease, with cases expected to climb to 200,000 by 2025. ... Having multiple Alzheimer’s research centers & programs, some would say Arizona is at the…READ MORE